J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
Trial status: Authorised
Safety Lead-in:Safety and Tolerability of vepugratinib in combination with EV and pembrolizumab, Safety Lead-in:Overall Response Rate (ORR), Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 117 participants
БГ